Costabel, Ulrich
Albera, Carlo
Glassberg, Marilyn K.
Lancaster, Lisa H.
Wuyts, Wim A.
Petzinger, Ute
Gilberg, Frank
Kirchgaessler, Klaus-Uwe
Noble, Paul W.
Funding for this research was provided by:
F. Hoffmann-La Roche, Ltd. (.)
Article History
Received: 21 November 2018
Accepted: 27 February 2019
First Online: 12 March 2019
Ethics approval and consent to participate
: The study was conducted in accordance with the Declaration of Helsinki, written informed consent was required from all patients participating in the study, and the institutional review board or ethics committee at each centre approved the study protocol.
: Not applicable.
: UC was a member of the CAPACITY trial steering committee and an advisor on IPF trials to Bayer, Biogen, Boehringer Ingelheim, F. Hoffmann-La Roche, Ltd., FibroGen, GlaxoSmithKline, Global Blood Therapeutics, InterMune/Roche and UCB Celltech, and has received lecture fees from AstraZeneca, Bayer, Boehringer Ingelheim and InterMune/Roche. CA was an advisor on IPF trials to F. Hoffmann-La Roche, Ltd. and FibroGen, and has received personal fees from Bayer, Boehringer Ingelheim, FibroGen, GlaxoSmithKline, InterMune/Roche, MSD and Sanofi. MKG was a member of the ASCEND study steering committee and an advisor for Bellerophon, Boehringer Ingelheim, Genentech, InterMune/Roche and Patara, and has received research grants from Genentech and InterMune/Roche. LHL reports research grants, prior advisory board, and disease state education from Genentech, research grants and disease state education from Boehringer Ingelheim, research grants from Celgene and Novartis, and research grants and consulting fees from Galapagos and Bellerophon outside of the submitted work. WAW is on the speaker bureaus for F. Hoffmann-La Roche, Ltd. and Boehringer Ingelheim; his institution has received research funding from both companies. UP was an employee of Clinipace-Accovion GmbH – a company contracted by F. Hoffmann-La Roche, Ltd. to perform analyses of study data – at the time of this study. FG is an employee of F. Hoffmann-La Roche, Ltd. K-UK is an employee and shareholder of F. Hoffmann-La Roche, Ltd. PWN was a member of the ASCEND and CAPACITY study steering committees and a consultant for Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, InterMune/Roche, Moerae Matrix and Takeda.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.